As per the recent report by FMI, global sales of the pelvic floor stimulators industry are projected to total USD 140.39 million for 2023. The demand outlook for the market remains buoyant as FMI forecasts it to exhibit a CAGR of 8.8% from 2023 to 2033, reaching USD 325.41 million by 2033.
The market growth in being induced by the following factors:
| Attribute | Details |
|---|---|
| Pelvic Floor Stimulators Market Size (2023) | USD 140.39 million |
| Pelvic Floor Stimulators Market Size (2033) | USD 325.41 million |
| Pelvic Floor Stimulators Forecast CAGR (2023 to 2033) | 8.8% |
| Pelvic Floor Stimulators Market Size (2022) | USD 129.04 million |
| Pelvic Floor Stimulators Historical CAGR (2018 to 2022) | 4.8% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Adopting telehealth facilities for pelvic floor care is expected to create attractive opportunities for manufacturers. The advent of telemedicine has improved access to care, enhanced resource productivity, and reduced costs related to traditional office visits in a wide array of medical fields.
Top healthcare institutes are adopting telehealth for patients' convenience to discuss pelvic floor dysfunction problems and other related disorders. With telehealth, HCPs could interact with patients sequestered in their homes. Hospitals like UCLA are now focusing on teleconsultation to reach people to provide support.
Despite urinary incontinence's social and financial burden, fewer than half of women with significant PFD symptoms pursue treatment. Besides this, women often feel personal embarrassment, unaware that PFDs are medical conditions and that treatment options exist. A lack of awareness is expected to continue restraining growth in the market.
Similarly, inadequate reimbursement policies in countries with poor economies are projected to hinder market growth. Insurance payers are reluctant to cover PFDs as the treatment mainly covers physical therapy. Some insurers consider physical therapy medically necessary with a provider referral.
Other insurers place a cap on visits they are going to cover per year. Affordability is a significant problem for a considerable chunk of the population due to the absence of health insurance and government support policies that cover treatment in developing countries such as India and China.
This absence of social health insurance and the exclusionary provision of private health insurance schemes significantly limit the pelvic floor stimulators industry.
FMI predicts the pelvic floor stimulator sales to record a surge at 8.8% CAGR between 2023 and 2033 as against sales growth of 4.8% registered in 2018 to 2022. Demand is projected to continue rising in response to the surging cases of urinary incontinence around the world.
According to sources from the National Association for Continence (NAFC), around 200 million adults are suffering from some form of urinary incontinence worldwide. It further states that the condition is more common in women and says that the United States accounts for 25 million adult patients, up to 80% being women.
Similarly, the growing incidence of diabetes and hypertension is a significant factor in the increase of patients suffering from urinary incontinence. This, in turn, is driving the demand for pelvic floor stimulators. FMI has predicted the demand for female stress urinary incontinence treatment devices to gain considerable momentum in the near future. This is projected to, in turn, present opportunities for pelvic floor stimulator market players to capitalize on.
According to a report published by the World Health Organization (WHO) in 2019, about 1.13 billion people have hypertension. Diabetes is the leading cause of advanced renal failure, followed by hypertension, which affects about one billion people worldwide.
Pelvic floor stimulators are often administered to offer advanced care to patients suffering from end-stage renal diseases. FMI sees this as a chief growth driver of the market. Coupled with this, technological advancements reported in the healthcare sector, besides the rising emphasis on non-invasive treatments, are projected to pave the way for the expansion of the market in the coming years.
Non-invasive treatments also stimulate muscle pathways and nerves without requiring active patient involvement, which is expected to drive the demand during the forecast period.
New products are being integrated with Bluetooth to connect with smartphones for real-time progress tracking without the risks of surgery or adverse effects associated with treatment. In February 2020, Atlantic Therapeutics (Ireland) received clearance from the FDA, allowing the wearable electric muscle stimulator device to be sold over the counter for treating stress urinary incontinence.
These developments are projected to remain crucial for the market, enabling pelvic floor stimulator manufacturers to up their game in the coming years.
The United States holds over 76% share of the North America pelvic floor stimulators industry. As per the Department of Health and Human Services of the United States, urinary incontinence is observed to be twice as common among women when compared with men.
This can be attributed to childbirth, pregnancy, and menopause. Urinary incontinence is not a normal part of aging and can be treated. Over the last decade, electrical stimulation has developed as one of the most advanced and unique types of biofeedback that can be used for pelvic floor muscle rehabilitation in the United States.
The growing inclination toward research and development is to find a cost-effective and efficient pelvic floor exercise method. Moreover, the rising focus on first-line conservative management programs for women suffering from urinary incontinence is a significant factor likely to fuel the adoption of pelvic floor stimulators in the United States.
| Country | The United Kingdom |
|---|---|
| Forecast CAGR (2023 to 2033) | 8.7% |
The United Kingdom accounts for over 25% share of the Europe market through the assessment period ending in 2033. The high prevalence of urinary incontinence, the surge in the adoption of technologically advanced products, a large base of medical device companies, and a massive pipeline of products drive demand.
The market in the United Kingdom is likely to expand at a high CAGR of 8.7% during the forecast period. Around 6 million people in the United Kingdom are suffering from urinary incontinence, according to the National Health Service (2017).
The Indian market accounts for more than 55% of the sales registered in South Asia in 2022. Various factors, such as growing investment by leading players, increasing government spending, and awareness programs by several government and non-government organizations, are driving the market growth.
The Urological Society of India enlisted guidelines for increasing awareness about urinary incontinence in the country. Furthermore, increasing healthcare expenditure due to the pandemic has created a greater scope for adoption. The growing population makes it a promising market in the coming years.
| Country | Australia |
|---|---|
| Forecast CAGR (2023 to 2033) | 10.6% |
The market for pelvic floor stimulators in Australia is exhibiting a 10.6% CAGR and is projected to account for more than 83% of the Oceania market throughout the projection period. Increasing government initiatives to create awareness is anticipated to boost regional market growth.
The Australian government has developed the Continence Aids Payment Scheme (CAPS) to support patients with severe incontinence problems with their needs. They have also launched National Continence Management Program to increase awareness about numerous bowel and bladder health problems.
Moreover, urologists, urogynecologists, gynecologists, nurses, and other skilled organizations have actively promoted awareness of urinary continence.
The International Continence Society (ICS) has created the Continence Promotion Committee (CPC) to encourage public awareness programs, education, and services, about urinary incontinence globally. Thus, a growth in awareness programs regarding pelvic floor diseases and the increasing incidence of urinary incontinence (UI) by different government and non-profit organizations are fueling the pelvic floor stimulator industry.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Segment | Electrical Stimulators |
|---|---|
| Forecast CAGR (2023 to 2033) | 9.1% |
Electrical stimulators have a higher potential for growth in the coming years. The segment is likely to expand with a high CAGR of 9.1% in the coming decade. Electrical stimulation has appeared as one of the advanced and unique biofeedback types used for pelvic floor muscle rehabilitation.
The growing inclination to find a cost-effective and efficient pelvic floor exercise method with a rising focus on first-line conservative management programs for urinary incontinence in women is likely to fuel the adoption of electrical stimulators.
The urinary incontinence segment is expected to contribute maximum revenue share in the global pelvic floor stimulators market. In terms of revenue, the urinary incontinence segment accounted for over 76% share in 2022.
Urinary incontinence is considered a significant health problem globally. It has a considerable economic and social impact on individuals and society. The rapid expansion of the geriatric population base is among the primary aspects leading to the increase in pelvic floor disorders.
As per estimates by the UNU (United Nations University), the percentage of the geriatric population above 65 is expected to rise to 16% by 2050 from 7% in 2000. Thus, the rising prevalence of urinary incontinence among elderly women in several regions has significantly driven the demand for pelvic floor stimulators.
| Segment | Hospitals |
|---|---|
| Forecast CAGR (2023 to 2033) | 9.2% |
Hospitals are leading the market, with significant growth in the pelvic floor stimulators industry, with a 9.2% CAGR in the forecast period. Similarly, hospitals can impact higher investment abilities and capital with improved admittance to cutting-edge technologies and patient care, projected to enhance the market growth in the long term.
Manufacturers in the pelvic floor stimulators market are primarily aiming to carry out strategic collaborations while investing in research and development to consolidate growth in a competitive and fragmented market. Key players are also expanding their global and regional presence through product launches, acquisitions, expansions, and upgrading distribution channels to penetrate the pelvic floor stimulators industry.
| Attribute | Details |
|---|---|
| Pelvic Floor Stimulators Market Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Pelvic Floor Stimulators Industry Analysis | USD million for Value in million |
| Key Countries Covered | The United States, Canada, the United Kingdom, Germany, Italy, France, Spain, Benelux, Russia, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa and North Africa |
| Key Segments Covered | Product Type, Application, End User, and Region |
| Pelvic Floor Stimulators Market - Key Companies Profiled | Medtronic Plc; Atlantic Therapeutics; Laborie Inc.; The Prometheus Group; Everyway Medical Instruments Co.; Ltd.; KayCo 2 Ltd.; InControl Medical Ltd.; Tic Medizintechnik GmbH; Shenzhen XFT Medical Ltd.; Chiaro Technology Ltd.; Zynex Inc.; Utah Medical Products; Inc.; Verity Medical Ltd. |
| Pelvic Floor Stimulators Market - Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market boosted at a CAGR of 4.8% from 2018 to 2022.
Through 2033, the market is to develop at a CAGR of 8.8%.
By 2033, the market is to have expanded to USD 325.41 million.
In 2023, the market is anticipated to reach a worth of USD 140.39 million.
The United States controls 76% of the North American market.
The Indian market accounts for more than 55% of all South Asian sales.
| Market Size (2023) | USD 258.91 million |
|---|---|
| Market Size (2033) | USD 341.26 million |
| Market CAGR (2023 to 2033) | 2.8% |
Explore Therapeutic Device Insights
View Reports
Pelvic Floor Stimulators Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
